Mizuho Securities analyst Siti Panigrahi maintained a Buy rating on Anaplan (PLAN – Research Report) on November 15 and set a price target of $90.00. The company’s shares closed last Wednesday at $60.54.
According to TipRanks.com, Panigrahi is a 5-star analyst with an average return of 20.5% and a 70.4% success rate. Panigrahi covers the Technology sector, focusing on stocks such as Zoom Video Communications, ZoomInfo Technologies, and Ceridian HCM Holding.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anaplan with a $82.59 average price target, which is a 34.2% upside from current levels. In a report released yesterday, Monness also maintained a Buy rating on the stock with a $101.00 price target.
Based on Anaplan’s latest earnings release for the quarter ending July 31, the company reported a quarterly revenue of $144 million and GAAP net loss of $51.12 million. In comparison, last year the company earned revenue of $107 million and had a GAAP net loss of $35.52 million.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PLAN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anaplan, Inc. engages in the provision of cloud-based connected planning platform that helps connect organizations and people to make better and faster decisions. It also offers professional services, including consulting, implementation, and training. The company was founded by Michael Gould, John David Guy Haddleton, and Sue Haddleton in 2006 and is headquartered in San Francisco, CA.
Read More on PLAN:
- Maxim Group Thinks CohBar’s Stock is Going to Recover
- Mizuho Securities Keeps Their Hold Rating on Coupa Software (COUP)
- Brainstorm Cell Therapeutics (BCLI) Gets a Buy Rating from Maxim Group
- SCYNEXIS (SCYX) Received its Third Buy in a Row
- Maxim Group Thinks Agile Therapeutics’ Stock is Going to Recover